Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Payables: 2017-2025

Historic Payables for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $33.7 million.

  • Crinetics Pharmaceuticals' Payables rose 84.28% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.8 million, marking a year-over-year increase of 32.60%. This contributed to the annual value of $21.5 million for FY2024, which is 7.45% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Payables of $33.7 million as of Q3 2025, which was down 11.58% from $38.1 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Payables' 5-year high stood at $38.1 million during Q2 2025, with a 5-year trough of $6.2 million in Q3 2021.
  • For the 3-year period, Crinetics Pharmaceuticals' Payables averaged around $25.3 million, with its median value being $23.2 million (2023).
  • In the last 5 years, Crinetics Pharmaceuticals' Payables decreased by 25.11% in 2021 and then spiked by 139.78% in 2022.
  • Crinetics Pharmaceuticals' Payables (Quarterly) stood at $8.5 million in 2021, then spiked by 81.28% to $15.4 million in 2022, then surged by 51.10% to $23.2 million in 2023, then decreased by 7.45% to $21.5 million in 2024, then soared by 84.28% to $33.7 million in 2025.
  • Its last three reported values are $33.7 million in Q3 2025, $38.1 million for Q2 2025, and $31.6 million during Q1 2025.